Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TRPV1 | Q8NER1 | 4/20 | 0.40 |
| ▸ | CNR1 | P21554 | 2/20 | 0.40 |
| ▸ | CNR2 | P34972 | 2/20 | 0.40 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.40 |
| ▸ | EPHX2 | P34913 | 3/20 | 0.39 |
| ▸ | MTNR1A | P48039 | 1/20 | 0.39 |
| ▸ | MTNR1B | P49286 | 1/20 | 0.39 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.38 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.37 |
| ▸ | TAS1R3 | Q7RTX0 | 1/20 | 0.37 |
| ▸ | TAS1R1 | Q7RTX1 | 1/20 | 0.37 |
| ▸ | TAS1R2 | Q8TE23 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8042544 | 0.88 | EPHX2 (0.54) | SIGMAR1ALDH1A1EPHX2EPHX1TAS1R3 | |
| SCHEMBL26253133 | 0.86 | KMT2A (0.33) | TRPV1CNR1CNR2SIGMAR1ALDH1A1 | |
| SCHEMBL20215892 | 0.85 | ALDH1A1 (0.44) | TRPV1CNR1CNR2SIGMAR1ALDH1A1 | |
| SCHEMBL13918751 | 0.83 | TRPV1 (0.44) | TRPV1CNR1CNR2MTNR1AMTNR1B | |
| SCHEMBL13918752 | 0.83 | TRPV1 (0.44) | TRPV1CNR1CNR2MTNR1AMTNR1B | |
| SCHEMBL23583172 | 0.79 | — | — | |
| SCHEMBL20807544 | 0.79 | — | — | |
| SCHEMBL21285287 | 0.79 | — | — | |
| SCHEMBL5021846 | 0.79 | USP2 (0.44) | ALDH1A1MTNR1AMTNR1BEPHX1L3MBTL1 | |
| SCHEMBL18794298 | 0.79 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4212180-A1 | MODIFIED THERAPEUTIC AGENTS, STAPLED PEPTIDE LIPID CONJUGATES, AND COMPOSITIONS THEREOF | The Scripps Research Institute (US) | 2023-07-19 | — | — | EP | disclosed |
| US-20160317623-A1 | MODIFIED THERAPEUTIC AGENTS, STAPLED PEPTIDE LIPID CONJUGATES, AND COMPOSITIONS THEREOF | THE SCRIPPS RESEARCH INSTITUTE | 2016-11-03 | — | — | US | disclosed |
| WO-2015095406-A1 | MODIFIED THERAPEUTIC AGENTS, STAPLED PEPTIDE LIPID CONJUGATES, AND COMPOSITIONS THEREOF | THE CALIFORNIA INSTITUTE FOR BIOMEDICAL RESEARCH (US) | 2015-06-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160317623-A1 | MODIFIED THERAPEUTIC AGENTS, STAPLED PEPTIDE LIPID CONJUGATES, AND COMPOSITIONS THEREOF | SGMS1, SGMS2, PHOSPHO1 | TRPV1 4470/4885CNR1 4666/4885CNR2 4636/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.